iRhythm (IRTC) Form 144: Marc Rosenbaum to Sell 226 Shares on NASDAQ
Rhea-AI Filing Summary
Form 144 filed for iRhythm Technologies (IRTC) shows an insider intends to sell a small block of common stock through Morgan Stanley Smith Barney on NASDAQ. The notice specifies 226 shares with an aggregate market value of $35,918.18, acquired under the company Employee Stock Purchase Plan on 11/30/2023 and paid for in cash. The filer previously sold 696 shares on 06/02/2025 for $97,586.16. With 32,127,763 shares outstanding reported on the form, the planned sale represents approximately 0.0007% of the outstanding shares, indicating the transaction is immaterial to total equity. The filer certifies there is no undisclosed material adverse information and includes standard Rule 10b5-1 language if applicable.
Positive
- None.
Negative
- None.
Insights
TL;DR Insider plans to sell a very small stake—transaction size is immaterial relative to shares outstanding.
The Form 144 discloses a proposed sale of 226 common shares valued at $35,918.18 through Morgan Stanley Smith Barney on NASDAQ. The shares were acquired via the Employee Stock Purchase Plan on 11/30/2023. A prior sale of 696 shares on 06/02/2025 generated $97,586.16. Relative to the 32,127,763 shares outstanding shown on the form, the current notice represents about 0.0007% of outstanding shares, which is unlikely to alter market perception or company valuation. Disclosure appears routine and consistent with insider liquidity under an ESPP.
TL;DR Filing reflects routine insider liquidity; no governance red flags evident from disclosed facts.
The notice includes required attestations that no undisclosed material adverse information exists and references possible Rule 10b5-1 instructions. The transaction size and prior recent sale suggest opportunistic, small-scale disposition of shares acquired through an ESPP rather than a vote of no confidence by management. All material items in the form are disclosed: acquisition method, payment type, broker, amounts, and past three-month sales, meeting regulatory transparency expectations.